Award: Boehringer Ingelheim is Global Top Employer 2022 Award: Boehringer Ingelheim is Global Top Employer 2022 Global Top Employer 2022
Closing healthcare gaps with continued vaccination campaigns Closing healthcare gaps with continued vaccination campaigns How we continue combating rabies through collaborative efforts and the use of drone delivery in rural Kenya.
Henke-Sass Wolf develop needle free device Henke-Sass Wolf develop needle free device Boehringer Ingelheim partners with Henke-Sass, Wolf to develop innovative needle free injection device for pigs
Boehringer Ingelheim partners with PetMedix Boehringer Ingelheim partners with PetMedix Partnering with PetMedix on Ky9™ platform cutting edge technology as a means to bring innovative new therapies to improve health of animals
Partnering in Central Nervous System Diseases Partnering in Central Nervous System Diseases We are looking for new early-science collaborations. Join our expanding community of innovation partners in central nervous system diseases.
Our Biotech Story | Bioxcellence | Boehringer Ingelheim Our Biotech Story | Bioxcellence | Boehringer Ingelheim Discover our pioneering history & leadership in biotechnology, driving innovation in biopharmaceutical manufacturing & breakthrough therapies.
Experiences of living with cancer Experiences of living with cancer We know from speaking with people living with cancer and their loved ones, that it’s often the small moments that can be the most significant.
Employees empower small dairy producers Employees empower small dairy producers Boehringer Ingelheim social intrapreneurship helps farmers improve animal welfare and the well-being of rural communities in Southern India.
BTD for GlyT1 in Schizophrenia BTD for GlyT1 in Schizophrenia Boehringer Ingelheim’s Investigational Treatment for Cognitive Impairment Associated with Schizophrenia receives FDA Breakthrough Therapy Designation
AI&Data Science Fellowship Tuebingen AI&Data Science Fellowship Tuebingen AI&Data Science Fellowship Tuebingen
Positive-CHMP-opinion-for-dabigatran-in-children Positive-CHMP-opinion-for-dabigatran-in-children Positive CHMP opinion received for use of dabigatran for the treatment and prevention of venous thromboembolic events in children
Announcement for Imagine - our new sustainability story hub Announcement for Imagine - our new sustainability story hub Discover Imagine, our sustainability story hub, showcasing how we drive health equity and advance sustainable healthcare solutions for a better future
A passion for research which addresses unmet medical needs A passion for research which addresses unmet medical needs Eric Haaksma, Head of Global Innovation Animal Health, explains why his professional purpose is rooted in helping drive advancements in scientific research
On two wheels for more animal health On two wheels for more animal health Cowtribe’s social entrepreneurs win Boehringer Ingelheim's Accelerator Program.
Ukraine Help: The heroes of Mainz-Finthen Ukraine Help: The heroes of Mainz-Finthen Travis Kelley helps Olena and Wasyl flee from Ukraine. This is the record of a dramatic and emotional rescue operation.
Our partners Bioveta Our partners Bioveta Our partner Bioveta shares insights about the longstanding collaboration with Boehringer Ingelheim and the evolution of the partnership
PRRS vaccine celebrates 25 years in Europe PRRS vaccine celebrates 25 years in Europe Boehringer Ingelheim celebrates 25 years to combat PRRS in Europe
Dirk Stenkamp Dirk Stenkamp Dirk Stenkamp, Senior Vice President Research Site Germany, reflects on our culture of collaboration and passion for progress.
emperor-preserved-heart-failure-toplineresults emperor-preserved-heart-failure-toplineresults Positive, top-line results announced from the EMPEROR-Preserved Phase III trial in adults with heart failure with preserved ejection fraction